Latest Breaking News On - Pooled analysis - Page 3 : comparemela.com

Philip J Mease, MD: New Data on Guselkumab for Psoriatic Arthritis Patients

This interview segment with Dr. Mease featured a discussion about data presented at ACR 2023 on guselkumab and patients with psoriatic arthritis.

Spondyloarthritis psPhilipj measeUniversity of washington school medicineSwedish medical centerAmerican college of rheumatologyDrug administrationJanssen pharmaceuticals incCorevitas psoriatic arthritisSpondyloarthritis registryJanssen pharmaceuticalsWashington schoolPatient reported outcomes throughGuselkumab treatmentPatients with active psoriatic arthritisReal world data fromCorevitas psoriatic

Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023

In-person and webcast event on Sunday, 10 December, 2023 at 8:00 AM PT / 4:00 PM GMTReview of pooled analysis of the ongoing FELIX Phase Ib/II study, pooled analysis from ALLCAR19 and FELIX Phase Ib.

United kingdomCity ofUnited statesSan diegoSan diego convention centerLauren williamsObecabtagene autoleucelJulia wilsonLydia leeSusana noonanClaire roddieResearch department of haematologyGlobenewswire incCancer instituteSa noonan communicationsUniversity college london

Final Round of Late-breaking Clinical Trial Results Announced at VIVA23

Final Round of Late-breaking Clinical Trial Results Announced at VIVA23
dicardiology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dicardiology.com Daily Mail and Mail on Sunday newspapers.

United statesRobert beasleySean lydenNicolas shammasWynn las vegasLate breaking clinical trialWynn lasVascular interventional advancesData fromWorld multicenter registryStates registryMonth outcomesSubgroup analysisVeryan medicalPooled analysis

Final Round of Late-Breaking Clinical Trial Results Announced at VIVA23

/PRNewswire/ The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and.

United statesWynn las vegasNicolas shammasSean lydenRobert beasleyLate breaking clinical trialWynn lasVascular interventional advancesData fromWorld multicenter registryStates registryMonth outcomesSubgroup analysisVeryan medicalPooled analysisThe viva foundation

Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute Congress

Analyses of pooled efficacy data from the EMERGENT program demonstrate significant improvements in schizophrenia symptoms Analyses extend prior findings that KarXT is generally well tolerated with.

Stephen brannanPeter weidenJudy kandoRenaissance school of medicineNeuroscience education instituteKaruna therapeutics incExchange commissionStony brook universitySecurities exchangeProgram of karKaruna therapeuticsColorado springsPooled results fromExecutive directorField medical leadMedical affairs